세계의 조영제 및 인젝터 시스템 시장 : 분석과 예측(2025-2035년)

Global Contrast Media Agent and Injector Systems Market: Analysis and Forecast, 2025-2035

US $ 4,900 ￦ 7,089,000

PDF and Excel (1-3 User License)

PDF 및 Excel 보고서를 동일 사업장에서 3명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 7,500 ￦ 10,851,000

PDF and Excel (Global License)

PDF 및 Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

세계 조영제 및 인젝터 시스템 시장은 CT 스캔, MRI, X-ray, 초음파 검사 등의 시술 시 체내 구조를 보다 선명하게 가시화하여 현대 영상진단에 필수적인 시장입니다.

조영제는 의료 전문가가 보다 효과적으로 이상을 감지할 수 있도록 이미지의 선명도를 향상시키기 위해 체내에 주입되는 특수한 물질입니다. 조영제의 사용은 다양한 영상 진단 기술에 매우 중요하며, 상세하고 정확한 진단을 보장합니다. 전 세계적으로 의료 수요가 증가함에 따라 영상 기술의 발전과 함께 조영제와 그 전달 시스템에 대한 수요가 증가하여 임상 현장에서 조영제의 중요성이 확고히 자리 잡고 있습니다.

세계 조영제 및 인젝터 시스템 시장을 주도하는 몇 가지 요인이 있습니다. 첫째, 암, 심혈관 질환, 신경 질환과 같은 만성 질환의 유병률 증가는 최적의 결과를 얻기 위해 조영제를 필요로 하는 첨단 영상 기술에 대한 수요를 증가시키고 있습니다. 세계보건기구(WHO)에 따르면 암으로만 매년 수백만 명이 사망하고 있어 조영제 사용에 크게 의존하는 조기 발견의 필요성이 강조되고 있습니다. 둘째, 3T MRI 및 4D CT 스캔과 같은 영상 기술의 끊임없는 발전은 보다 선명하고 상세한 영상을 제공하기 위해 보다 정교하고 고품질의 조영제 사용을 필요로 합니다. 셋째, 세계 인구의 고령화로 인해 영상 진단의 빈도가 증가함에 따라 효과적인 조영제의 필요성이 더욱 커지고 있습니다. 마지막으로, 진단 정확도 향상과 질병 조기 발견에 대한 수요 증가는 조영제를 의료 시스템에 필수적인 요소로 만들고 있습니다.

큰 성장 촉진요인에도 불구하고, 조영제 및 인젝터 시스템 시장은 몇 가지 문제에 직면해 있습니다. 가장 큰 우려는 알레르기 반응과 신장 독성을 포함한 조영제로 인한 부작용의 가능성입니다. 이러한 안전성 우려는 특히 기저질환이 있는 환자에서 특정 조영제의 사용을 제한할 수 있으며, 이로 인해 시장에서의 채택이 제한될 수 있습니다. 또한, 조영제 및 그에 따른 영상 진단의 높은 비용은 특히 의료 예산이 제한된 중저소득 국가에서는 장벽이 될 수 있습니다. 또한, 새로운 조영제 및 주입 시스템의 승인에 많은 시간과 비용이 소요되기 때문에 시장 도입이 지연되는 규제상의 문제도 있습니다.

조영제 및 주입기 시스템 시장에는 많은 기회가 있습니다. 아시아태평양 및 아프리카 일부 지역과 같은 신흥 시장에서는 의료 인프라가 확대되고 있으며, 이들 지역에서는 영상 진단에 대한 접근성이 확대됨에 따라 조영제에 대한 수요가 증가할 것으로 예상됩니다. 또한, 환자 개인별 맞춤 치료에 중점을 둔 정밀의료의 부상으로 정확한 진단 결과를 제공할 수 있는 보다 전문적인 조영제에 대한 수요가 증가하고 있습니다. 조영제가 분자 수준에서 더 높은 정확도를 제공하도록 설계되는 나노기술과 이미징 시스템을 변화시키는 인공지능(AI)의 혁신은 시장에 흥미로운 기회를 제공합니다. 나노 입자 기반 조영제는 스캔의 고감도 및 고해상도를 가능하게 함으로써 이미징 기술에 혁명을 일으켜 의료 전문가에게 새로운 길을 열어줄 것으로 기대됩니다.

세계의 조영제 및 인젝터 시스템 시장에 대해 조사했으며, 시장 개요와 함께 제품별/용도별/최종사용자별/지역별 동향, 시장 진출 기업 프로파일 등의 정보를 전해드립니다.

목차

주요 요약

조사 범위

제1장 세계의 조영제 및 인젝터 시스템 시장 개요

• 시장 전망
• 업계 전망
• 시장 역학

제2장 세계의 조영제 및 인젝터 시스템 시장 규모 분석(달러) 2024-2035년, 제품 유형별

• 시장 개요
• 성장 점유율 매트릭스
• 조영제
• 인젝터 시스템

제3장 세계의 조영제 및 인젝터 시스템 시장 규모 분석(달러) 2024-2035년, 용도별

• 시장 개요
• 성장 점유율 매트릭스
• 방사선과
• 심장병과
• 종양과
• 신경과
• 기타(비뇨기과, 소화기과 등)

제4장 세계의 조영제 및 인젝터 시스템 시장 규모 분석(달러) 2024-2035년, 최종사용자별

• 시장 개요
• 성장 점유율 매트릭스
• 병원
• 영상진단센터
• 기타(ASC, 연구기관 등)

제5장 세계의 조영제 및 인젝터 시스템 시장 규모 분석(달러) 2024-2035년, 지역별

• 시장 개요

제6장 세계의 조영제 및 인젝터 시스템 시장 - 경쟁 벤치마킹과 기업 개요

• 경쟁 벤치마킹
• 경쟁 구도
  • 각사 주요 전략과 전개
  • 주요 발전 분석
  • 시장 점유율 분석, 2024년
• 기업 개요
  • Bayer AG
  • Beijing Beilu Pharmaceutical Co. Ltd.
  • Bracco Group
  • Fresenius SE & Co. KGaA
  • FUJIFILM Holdings Corporation
  • General Electric Company
  • Guerbet
  • Jiangsu Hengrui Pharmaceutical Co., Ltd
  • Jodas Expoim Pvt. Ltd
  • Lantheus Holdings, Inc.
  • Shenzen Seacrown Electromechanical Co., Ltd
  • Sino Medical-Device Technology Co., Ltd
  • ulrich GmbH & Co. KG
  • Unijules Life Sciences Ltd
  • 기타 주요 기업

LSH

영문 목차

영문목차

Global Contrast Media Agent and Injector System Market Industry Overview

The global contrast media agent and injector system market is integral to modern diagnostic imaging, providing enhanced visualization of internal body structures during procedures like CT scans, MRIs, X-rays, and ultrasounds. Contrast media agents are specialized substances injected into the body to improve the clarity of images, allowing healthcare professionals to detect abnormalities more effectively. The use of contrast media agents is crucial for a variety of imaging techniques, ensuring detailed and accurate diagnostics. As healthcare needs increase globally, coupled with advancements in imaging technology, the demand for contrast media agents and their delivery systems is rising, solidifying their importance in clinical practice.

Several factors are driving the global contrast media agent and injector system market. First, the growing prevalence of chronic diseases, such as cancer, cardiovascular disease, and neurological disorders, has elevated the demand for advanced imaging technologies that require contrast media agents for optimal results. According to the World Health Organization (WHO), cancer alone accounts for millions of deaths each year, emphasizing the need for early detection, which heavily relies on the use of contrast media agents. Second, continuous advancements in imaging technologies, such as 3T MRIs and 4D CT scans, necessitate the use of more sophisticated and higher-quality contrast media agents to deliver clearer, more detailed images. Third, the aging global population is leading to an increased frequency of diagnostic imaging procedures, further boosting the need for effective contrast media agents. Lastly, the rising demand for greater diagnostic accuracy and early disease detection is making contrast media agents indispensable in the healthcare system.

Despite the substantial growth drivers, the contrast media agent and injector system market for contrast media agents faces several challenges. A major concern is the potential for adverse reactions to contrast media agents, including allergic reactions or nephrotoxicity. These safety concerns can restrict the use of certain contrast media agents, particularly in patients with pre-existing conditions, which in turn limits their market adoption. Furthermore, the high cost of contrast media agents and the associated imaging procedures can act as a barrier, especially in low- and middle-income countries where healthcare budgets are more constrained. Regulatory hurdles also pose challenges, as obtaining approval for new contrast media agents and injector systems can be a lengthy and costly process, delaying their introduction to the market.

The contrast media agent and injector system market presents numerous opportunities. The growing healthcare infrastructure in emerging markets, such as Asia-Pacific and parts of Africa, is expected to boost demand for contrast media agents as these regions expand access to diagnostic imaging. Additionally, the rise of precision medicine, which focuses on tailoring treatments to individual patients, is driving the demand for more specialized contrast media agents that can provide precise diagnostic results. Innovations in nanotechnology, where contrast media agents are designed at the molecular level to offer higher precision, and artificial intelligence (AI), which is transforming imaging systems, present exciting opportunities for the market. Nanoparticle-based contrast media agents are expected to revolutionize imaging techniques by enabling higher sensitivity and resolution in scans, opening new avenues for healthcare professionals.

Global Contrast Media Agent and Injector System Market Lifecycle Stage

The global contrast media agent and injector system market is experiencing significant growth, with multiple collaborations between key market players aimed at combining resources, expanding customer bases, and enhancing marketing efforts. This growth is further supported by continuous research and development focused on creating innovative products. Additionally, many pharmaceutical companies are broadening their operations and becoming more outsourcing-oriented, which is helping to drive the expansion of the contrast media agent and injector system market.

Industry and Technology Overview

Market Segmentation:

Segmentation 1: by Product

• Contrast Media Agents
• Injector Systems

The global contrast media agent and injector system market (by product) is expected to be dominated by the contrast media agents segment.

• Contrast Media Agents (by Modality)
  • X-Ray/CT Scan
  • MRI
  • Ultrasound

The global contrast media agent market (by modality) is expected to be dominated by the X-Ray/CT scan.

• Contrast Media Agents (by Type of Media Agent)
  • Iodine-Based Contrast Media Agent
  • Gadolinium-Based Contrast Media Agent
  • Barium-Based Contrast Media Agent
  • Microbubble Contrast Media Agent
  • Others

The global contrast media agent market (by type of media agent) is expected to be dominated by iodine-based contrast media agent.

• Injector Systems (by Modality)
  • CT Injector Systems
  • MRI Injector Systems
  • Cardiovascular/Angiography Injector Systems

The global contrast media injector system market (by modality) is expected to be dominated by CT injector systems.

• Injector Systems (by Product)
  • Injector
  • Consumables and Accessories

The global contrast media injector system market (by product) is expected to be dominated by consumables and accessories.

• Injector Systems (by Injector Type)
  • Single-Head Injectors
  • Dual-Head Injectors
  • Syringeless Injectors

The global contrast media injector system market (by injector type) is expected to be dominated by single-head injectors.

Segmentation 2: by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest-of-Europe
• Asia-Pacific
  • China
  • Japan
  • India
  • Australia
  • Rest-of-Asia-Pacific
• Rest-of-the-World

The global contrast media agent and injector system market (by region) is dominated by the North America region.

Recent Developments in Global Contrast Media Agent and Injector System Market

• In January 2023, Bayer AG received European approval for its iodine-based contrast agents, Ultravist-300 and Ultravist-370, for use in contrast-enhanced mammography (CEM).
• In December 2022, Beijing Beilu Pharmaceutical Co. Ltd. expanded its operations by establishing a wholly-owned subsidiary in Hong Kong.
• In April 2022, Beijing Beilu Pharmaceutical Co., Ltd. received the "Drug Registration Certificate" from the National Medical Products Administration (NMPA) for its gadobutrol injection.
• In February 2023, Bracco Group formed a partnership with Wellstar Health System to conduct trials for its FDA-approved VUEWAY (gadopiclenol) injection, a contrast agent designed for MRI applications.
• In February 2023, Bracco Group acquired all shares of Bracco-Eisai from Eisai and subsequently rebranded the company as Bracco Japan, Ltd.
• In July 2022, Fresenius Kabi, a subsidiary of Fresenius SE & Co. KGaA, launched its line of generic contrast media agents in the U.S.
• In December 2022, General Electric Company partnered with ulrich GmbH & Co. KG to introduce a branded multi-dose contrast media injector in the U.S. market.

Demand - Drivers and Limitations

The following are the drivers for the global contrast media agent and injector system market:

• Increasing prevalence of cancer and cardiovascular diseases leading to an upsurge in demand for imaging with contrast media agent and injector system
• Upsurge in demand for image-guided diagnostics
• Growing number of regulatory approvals

The global contrast media agent and injector system market is expected to face some limitations as well due to the following challenges:

• Rising health concerns post usage of contrast media agents in the body

How can this report add value to an organization?

Growth/Marketing Strategy: The global contrast media agent and injector system market has seen major development by key players operating in the market, such as business expansion, partnership, collaboration, and joint ventures.

Competitive Strategy: The global contrast media agent and injector system market consists of various leading manufacturers, small-medium enterprises, and emerging startups. With the increasing demand for advanced devices, companies have the opportunity to expand their presence in the market through different strategic approaches. Some of the strategies followed by the leading contributors are the launch of new products, mergers and acquisitions, and regulatory and legal approvals.

Competitive Landscape

The contrast media agent and injector system market is highly competitive, with major players focusing on product innovation and strategic expansion.

Contrast Media Agent And Injector System Key Market Players and Competition Synopsis:

• Bayer AG
• Fresenius SE & Co. KGaA
• FUJIFILM Visualsonics, Inc (Fujifilm Holdings Corporation)
• General Electric Company
• Lantheus Medical Imaging
• Guerbet
• Bracco Group
• J.B. Chemicals and Pharmaceuticals Ltd.
• Jiangsu Hengrui Medicine Co., Ltd.
• ulrich GmbH & Co. KG
• ShenzenSeacrown Electromechanical Co Ltd
• Jodas Expoim Pvt. Ltd.
• Beijing Beilu Pharmaceutical Co. Ltd
• MEDTRON AG
• SINO MDT
• Stanex Drugs & Chemical Pvt. Ltd.
• Taejoon Pharm
• Nano Therapeutics Pvt. Ltd.
• Nemoto Kyorindo Co., Ltd.

Table of Contents

Executive Summary

Scope of the Study

Research Methodology

1. Global Contrast Media Agent and Injector Systems Market Overview

• 1.1 Market Outlook
  • 1.1.1 Definitions
  • 1.1.2 Inclusion and Exclusion Criteria
  • 1.1.3 Market Size, 2024 - 2035 (US$)
  • 1.1.4 Market Growth Scenario
    • 1.1.4.1 Realistic Scenario
    • 1.1.4.2 Optimistic Scenario
    • 1.1.4.3 Pessimistic Scenario
• 1.2 Industry Outlook
  • 1.2.1 Market Overview
  • 1.2.2 Market Ecosystem
  • 1.2.3 Regulatory Landscape
    • 1.2.3.1 Regulatory and Legal Requirements and Framework in the U.S.
    • 1.2.3.2 Regulatory and Legal Requirements and Framework in Europe
    • 1.2.3.3 Regulatory and Legal Requirements and Framework in Asia-Pacific
    • 1.2.3.4 Regulatory and Legal Requirements and Framework in Other Key Countries
  • 1.2.4 Patent Analysis
    • 1.2.4.1 Patent Filing Trend (by Year)
    • 1.2.4.2 Patent Filing Trend (by Country)
• 1.3 Market Dynamics
  • 1.3.1 Market Key Trends
  • 1.3.2 Market Drivers
    • 1.3.2.1 Impact Analysis
  • 1.3.3 Market Restraints
    • 1.3.3.1 Impact Analysis
  • 1.3.4 Market Opportunities
    • 1.3.4.1 Impact Analysis

2. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Product Type

• 2.1 Market Overview
• 2.2 Growth Share Market
• 2.3 Contrast Media Agent
  • 2.3.1 By Modality
    • 2.3.1.1 X-Ray/CT scan
    • 2.3.1.2 MRI
    • 2.3.1.3 Ultrasound
  • 2.3.2 By Type of Media Agent
    • 2.3.2.1 Iodine-Based Contrast Media Agent
    • 2.3.2.2 Gadolinium-Based Contrast Media Agent
    • 2.3.2.3 Barium-Based Contrast Media Agent
    • 2.3.2.4 Microbubble Contrast Media Agent
    • 2.3.2.5 Others
• 2.4 Injector System
  • 2.4.1 By Product
    • 2.4.1.1 Injector
    • 2.4.1.2 Consumable and Accessories
  • 2.4.2 By Modality
    • 2.4.2.1 CT Injector Systems
    • 2.4.2.2 MRI Injector Systems
    • 2.4.2.3 Cardiovascular/Angiography Injector Systems
  • 2.4.3 By Injector Type
    • 2.4.3.1 Single Head Injectors
    • 2.4.3.2 Dual Head Injectors
    • 2.4.3.3 Syringeless Injectors

3. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Application

• 3.1 Market Overview
• 3.2 Growth Share Market
• 3.3 Radiology
• 3.4 Cardiology
• 3.5 Oncology
• 3.6 Neurology
• 3.7 Others (Urology, Gastroenterology, etc.)

4. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by End User

• 4.1 Market Overview
• 4.2 Growth Share Market
• 4.3 Hospitals
• 4.4 Diagnostic Imaging Centers
• 4.5 Others (ASCs, Research Institutes, etc.)

5. Global Contrast Media Agent and Injector Systems Market Analysis in Size (US$) 2024-2035, by Region

• 5.1 Market Overview
  • 5.1.1 Market Dynamics
  • 5.1.2 Market Size and Forecast
    • 5.1.2.1 North America Contrast Media Agent and Injector Systems Market
      • 5.1.2.1.1 Key Findings
      • 5.1.2.1.2 Market Dynamics
      • 5.1.2.1.3 Impact Analysis
      • 5.1.2.1.4 Market Sizing and Forecast
        • 5.1.2.1.4.1 North America Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.1.4.2 North America Contrast Media Injector System Market (by Product)
        • 5.1.2.1.4.3 North America Contrast Media Agent and Injector System Market (by Country)
        • 5.1.2.1.4.3.1 U.S.
        • 5.1.2.1.4.3.1.1 U.S. Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.1.4.3.1.2 U.S. Contrast Media Injector System Market (by Product)
        • 5.1.2.1.4.3.2 Canada.
        • 5.1.2.1.4.3.2.1 Canada Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.1.4.3.2.2 Canada Contrast Media Injector System Market (by Product)
    • 5.1.2.2 Europe Contrast Media Agent and Injector Systems Market
      • 5.1.2.2.1 Key Findings
      • 5.1.2.2.2 Market Dynamics
      • 5.1.2.2.3 Impact Analysis
      • 5.1.2.2.4 Market Sizing and Forecast
        • 5.1.2.2.4.1 Europe Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.2 Europe Contrast Media Injector System Market (by Product)
        • 5.1.2.2.4.3 Europe Contrast Media Agent and Injector System Market (by Country)
        • 5.1.2.2.4.3.1 U.K.
        • 5.1.2.2.4.3.1.1 U.K. Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.3.1.2 U.K. Contrast Media Injector System Market (by Product)
        • 5.1.2.2.4.3.2 Germany.
        • 5.1.2.2.4.3.2.1 Germany Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.3.2.2 Germany Contrast Media Injector System Market (by Product)
        • 5.1.2.2.4.3.3 France
        • 5.1.2.2.4.3.3.1 France Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.3.3.2 France Contrast Media Injector System Market (by Product)
        • 5.1.2.2.4.3.4 Italy
        • 5.1.2.2.4.3.4.1 Italy Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.3.4.2 Italy Contrast Media Injector System Market (by Product)
        • 5.1.2.2.4.3.5 Spain
        • 5.1.2.2.4.3.5.1 Spain. Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.3.5.2 Spain Contrast Media Injector System Market (by Product)
        • 5.1.2.2.4.3.6 Rest of Europe.
        • 5.1.2.2.4.3.6.1 Rest of Europe Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.2.4.3.6.2 Rest of Europe Contrast Media Injector System Market (by Product)
    • 5.1.2.3 Asia-Pacific Contrast Media Agent and Injector Systems Market
      • 5.1.2.3.1 Key Findings
      • 5.1.2.3.2 Market Dynamics
      • 5.1.2.3.3 Impact Analysis
      • 5.1.2.3.4 Market Sizing and Forecast
        • 5.1.2.3.4.1 Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.2 Asia-Pacific Contrast Media Injector System Market (by Product)
        • 5.1.2.3.4.3 Asia-Pacific Contrast Media Agent and Injector System Market (by Country)
        • 5.1.2.3.4.3.1 China
        • 5.1.2.3.4.3.1.1 China Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.3.1.2 China Contrast Media Injector System Market (by Product)
        • 5.1.2.3.4.3.2 Japan
        • 5.1.2.3.4.3.2.1 Japan Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.3.2.2 Japan Contrast Media Injector System Market (by Product)
        • 5.1.2.3.4.3.3 India
        • 5.1.2.3.4.3.3.1 India Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.3.3.2 India Contrast Media Injector System Market (by Product)
        • 5.1.2.3.4.3.4 Australia
        • 5.1.2.3.4.3.4.1 Australia Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.3.4.2 Australia Contrast Media Injector System Market (by Product)
        • 5.1.2.3.4.3.5 South Korea
        • 5.1.2.3.4.3.5.1 South Korea Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.3.5.2 South Korea Contrast Media Injector System Market (by Product)
        • 5.1.2.3.4.3.6 Rest-of- Asia-Pacific
        • 5.1.2.3.4.3.6.1 Rest-of-Asia-Pacific Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.3.4.3.6.2 Rest-of-Asia-Pacific Contrast Media Injector System Market (by Product)
    • 5.1.2.4 Latin America Contrast Media Agent and Injector Systems Market
      • 5.1.2.4.1 Key Findings
      • 5.1.2.4.2 Market Dynamics
      • 5.1.2.4.3 Impact Analysis
      • 5.1.2.4.4 Market Sizing and Forecast
        • 5.1.2.4.4.1 Latin America Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.4.4.2 Latin America Contrast Media Injector System Market (by Product)
        • 5.1.2.4.4.3 Latin America Contrast Media Agent and Injector System Market (by Country)
        • 5.1.2.4.4.3.1 Brazil
        • 5.1.2.4.4.3.1.1 Brazil Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.4.4.3.1.2 Brazil Contrast Media Injector System Market (by Product)
        • 5.1.2.4.4.3.2 Mexico
        • 5.1.2.4.4.3.2.1 Mexico Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.4.4.3.2.2 Mexico Contrast Media Injector System Market (by Product)
        • 5.1.2.4.4.3.3 Rest-of-Latin America
        • 5.1.2.4.4.3.3.1 Rest-of-Latin America Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.4.4.3.3.2 Rest-of-Latin America Contrast Media Injector System Market (by Product)
    • 5.1.2.5 Middle East and Africa Contrast Media Agent and Injector Systems Market
      • 5.1.2.5.1 Key Findings
      • 5.1.2.5.2 Market Dynamics
      • 5.1.2.5.3 Impact Analysis
      • 5.1.2.5.4 Market Sizing and Forecast
        • 5.1.2.5.4.1 Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.5.4.2 Middle East and Africa Contrast Media Injector System Market (by Product)
        • 5.1.2.5.4.3 Middle East and Africa Contrast Media Agent and Injector System Market (by Country)
        • 5.1.2.5.4.3.1 UAE
        • 5.1.2.5.4.3.1.1 UAE Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.5.4.3.1.2 UAE Contrast Media Injector System Market (by Product)
        • 5.1.2.5.4.3.2 South Africa
        • 5.1.2.5.4.3.2.1 South Africa Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.5.4.3.2.2 South Africa Contrast Media Injector System Market (by Product)
        • 5.1.2.5.4.3.3 Rest-of-MEA
        • 5.1.2.5.4.3.3.1 Rest-of-Middle East and Africa Contrast Media Agent and Injector System Market (by Product)
        • 5.1.2.5.4.3.3.2 Rest-of-Middle East and Africa Contrast Media Injector System Market (by Product)

6. Global Contrast Media Agent and Injector Systems Market- Competitive Benchmarking and Company Profiles

• 6.1 Competitive Benchmarking
• 6.2 Competitive Landscape
  • 6.2.1 Key Strategies and Developments by Company
    • 6.2.1.1 Funding Activities
    • 6.2.1.2 Mergers and Acquisitions
    • 6.2.1.3 Regulatory Approvals
    • 6.2.1.4 Partnerships, Collaborations, and Business Expansions
  • 6.2.2 Key Developments Analysis
  • 6.2.3 Market Share Analysis, 2024
• 6.3 Company Profiles
  • 6.3.1 Bayer AG
    • 6.3.1.1 Company Overview
    • 6.3.1.2 Product Portfolio/Offering
    • 6.3.1.3 Key Competitors
    • 6.3.1.4 Analyst View
  • 6.3.2 Beijing Beilu Pharmaceutical Co. Ltd.
    • 6.3.2.1 Company Overview
    • 6.3.2.2 Product Portfolio/Offering
    • 6.3.2.3 Key Competitors
    • 6.3.2.4 Analyst View
  • 6.3.3 Bracco Group
    • 6.3.3.1 Company Overview
    • 6.3.3.2 Product Portfolio/Offering
    • 6.3.3.3 Key Competitors
    • 6.3.3.4 Analyst View
  • 6.3.4 Fresenius SE & Co. KGaA
    • 6.3.4.1 Company Overview
    • 6.3.4.2 Product Portfolio/Offering
    • 6.3.4.3 Key Competitors
    • 6.3.4.4 Analyst View
  • 6.3.5 FUJIFILM Holdings Corporation
    • 6.3.5.1 Company Overview
    • 6.3.5.2 Product Portfolio/Offering
    • 6.3.5.3 Key Competitors
    • 6.3.5.4 Analyst View
  • 6.3.6 General Electric Company
    • 6.3.6.1 Company Overview
    • 6.3.6.2 Product Portfolio/Offering
    • 6.3.6.3 Key Competitors
    • 6.3.6.4 Analyst View
  • 6.3.7 Guerbet
    • 6.3.7.1 Company Overview
    • 6.3.7.2 Product Portfolio/Offering
    • 6.3.7.3 Key Competitors
    • 6.3.7.4 Analyst View
  • 6.3.8 Jiangsu Hengrui Pharmaceutical Co., Ltd
    • 6.3.8.1 Company Overview
    • 6.3.8.2 Product Portfolio/Offering
    • 6.3.8.3 Key Competitors
    • 6.3.8.4 Analyst View
  • 6.3.9 Jodas Expoim Pvt. Ltd
    • 6.3.9.1 Company Overview
    • 6.3.9.2 Product Portfolio/Offering
    • 6.3.9.3 Key Competitors
    • 6.3.9.4 Analyst View
  • 6.3.10 Lantheus Holdings, Inc.
    • 6.3.10.1 Company Overview
    • 6.3.10.2 Product Portfolio/Offering
    • 6.3.10.3 Key Competitors
    • 6.3.10.4 Analyst View
  • 6.3.11 Shenzen Seacrown Electromechanical Co., Ltd
    • 6.3.11.1 Company Overview
    • 6.3.11.2 Product Portfolio/Offering
    • 6.3.11.3 Key Competitors
    • 6.3.11.4 Analyst View
  • 6.3.12 Sino Medical-Device Technology Co., Ltd
    • 6.3.12.1 Company Overview
    • 6.3.12.2 Product Portfolio/Offering
    • 6.3.12.3 Key Competitors
    • 6.3.12.4 Analyst View
  • 6.3.13 ulrich GmbH & Co. KG
    • 6.3.13.1 Company Overview
    • 6.3.13.2 Product Portfolio/Offering
    • 6.3.13.3 Key Competitors
    • 6.3.13.4 Analyst View
  • 6.3.14 Unijules Life Sciences Ltd
    • 6.3.14.1 Company Overview
    • 6.3.14.2 Product Portfolio/Offering
    • 6.3.14.3 Key Competitors
    • 6.3.14.4 Analyst View
  • 6.3.15 Other Key Companies

관련자료